Does the Visual Field Improve After Initiation of Intraocular Pressure Lowering in the United Kingdom Glaucoma Treatment Study?

PURPOSE

Evidence to support the hypothesis that visual field (VF) status can improve after initiation of intraocular pressure (IOP) reducing treatment is controversial. We take advantage of participant eligibility data from the United Kingdom Glaucoma Treatment Study (UKGTS) to test this hypothesis in newly diagnosed glaucomatous patients randomized to IOP-lowering therapy or placebo.

DESIGN

Multicentre, randomized, triple-masked, placebo-controlled trial.

METHODS

Participants were newly diagnosed open-angle glaucoma patients in the UKGTS with eligibility and baseline data (n = 202 and n = 205 participants from the treatment and placebo groups, respectively). UKGTS eligibility data, including two reliable VFs (Humphrey 24-2 SITA Standard) and IOP measurements were compared to UKGTS trial baseline data acquired after allocation to treatment (topical prostaglandin analog) or placebo eye drops. Mean change in VF mean deviation (MD) and proportion of eyes that improved MD by more than different thresholds were compared across this interval in the treatment and placebo groups. Secondary analyses included stratifying the groups by level of IOP, level of VF loss, and age, along with pointwise analyses including change in subsets of VF locations. The main outcome measure was the mean change in VF MD.

RESULTS

Mean (standard deviation [SD]) time between eligibility/baseline visits and reduction in IOP was 12 (3) weeks and 4.8 (4.2) and 1.0 (3.6) mmHg for the treated and placebo eyes, respectively. Mean (SD) change in MD was almost the same for the treated (-0.03 [1.45] dB) and placebo groups (+0.08 [1.72] dB; P = .47). The proportions of participants with an MD improvement of 1 dB or more were similar for both groups (P = .25). No association was found between MD improvement and magnitude of IOP lowering. Stratifying data by IOP, level of VF loss and age did not reveal any differences between the treated and placebo groups, nor did any of the pointwise VF analyses.

CONCLUSIONS

Initial short-term VF changes in the treatment and placebo arms of UKGTS were the same. In these newly diagnosed patients with non-advanced glaucoma, we found no evidence to support the hypothesis that VF status improves after initial lowering of IOP by medical therapy.